Hepatitis C
DDW 2013: Advanced Fibrosis Does Not Affect Response to Faldaprevir All-oral Regimen
- Details
- Category: HCV Treatment
- Published on Wednesday, 22 May 2013 00:00
An interferon-free combination of faldaprevir, BI 207127, and ribavirin produced high and similar sustained response rates for treatment-naive genotype 1b hepatitis C patients with either absent-to-moderate liver fibrosis or advanced fibrosis/cirrhosis, according to a presentation at the Digestive Disease Week conference (DDW 2013) this week in Orlando.
DDW 2013: Viral Breakthrough May Occur during Interferon/Ribavirin 'Tail' of HCV Triple Therapy
- Details
- Category: HCV Treatment
- Published on Wednesday, 22 May 2013 00:00
HCV viral breakthrough is a continued possibility during the pegylated interferon/ribavirin continuation phase after triple therapy with telaprevir (Incivek or Incivek or Incivo), especially for difficult-to-treat patients, researchers reported this week at the Digestive Disease Week conference (DDW 2013) in Orlando.
Sunday is Hepatitis Testing Day -- All Baby Boomers Should Get Hep C Test
- Details
- Category: HCV Testing & Diagnosis
- Published on Wednesday, 15 May 2013 00:00
May 19 is the second annual Viral Hepatitis Testing Day, an opportunity to raise awareness among healthcare providers and the public about screening for chronic hepatitis B and C. According to the Centers for Disease Control and Prevention (CDC), an estimated 75% of people with hepatitis C virus (HCV) are not aware they are infected.
DDW 2013: Does Treating Herpes Help Suppress Hepatitis C Virus?
- Details
- Category: HCV Treatment
- Published on Wednesday, 22 May 2013 00:00
Treating herpes simplex virus type 2 (HSV-2) with valacyclovir (Valtrex) was associated with a substantial reduction in plasma hepatitis C virus levels in dually infected individuals, according to a small study presented at the Digestive Disease Week conference (DDW 2013)this week in Orlando.
HCV Protease Inhibitor Simeprevir Granted FDA Priority Review Status
- Details
- Category: HCV Treatment
- Published on Wednesday, 15 May 2013 00:00
On May 13, Janssen announced that its application for approval of the next-generation hepatitis C virus NS3/4A protease inhibitor simeprevir (formerly TMC435) has received priority review status from the U.S. Food and Drug Administration (FDA), giving it an estimated timeline of 6 months.
EASL 2013: Probiotics May Help Manage Hepatic Encephalopathy in Patients with Cirrhosis
- Details
- Category: HCV Disease Progression
- Published on Wednesday, 22 May 2013 00:00
Probiotics that change the population of organisms in the gut can help improve neurocognitive function and prevent hepatic encephalopathy in people with liver cirrhosis, according to a presentation last month at the EASL International Liver Congress (EASL 2013) in Amsterdam.
EASL 2013: Direct-acting Antivirals Boost Response to Pegylated Interferon/Ribavirin
- Details
- Category: HCV Treatment
- Published on Wednesday, 15 May 2013 00:00
For people with chronic hepatitis C who cannot wait for all-oral regimens, interferon-based therapy is still a reality. Researchers at the recent EASL International Liver Congress (EASL 2013) presented promising data showing that several experimental direct-acting antiviral agents (DAAs) can significantly improve response rates without reducing tolerability.
DDW 2013: Simeprevir Boosts Response to Interferon-based Therapy for Prior Relapsers
- Details
- Category: HCV Treatment
- Published on Wednesday, 22 May 2013 00:00
Adding the HCV protease inhibitor simeprevir (formerly TMC435) to pegylated interferon and ribavirin cured 79% of prior relapsers, and most were eligible to complete treatment after 3 months, according to findings from the PROMISE study presented at the Digestive Disease Week meeting (DDW 2013) this week in Orlando.
EASL 2013: Anemia Is a Common Side Effect of First-generation HCV Protease Inhibitors
- Details
- Category: HCV Treatment
- Published on Wednesday, 15 May 2013 00:00
About half of patients taking boceprevir (Victrelis) or telaprevir (Incivek or Incivo) developed anemia and approximately one-third experienced skin rash, but sustained response rates were high in an analysis of a population representative of people with chronic hepatitis C in North America, researchers reported at the EASL International Liver Congress (EASL 2013) last month in Amsterdam.
More Articles...
- EASL 2013: ACH-3102 and Sovaprevir Show Potent Activity, High Barrier to Resistance in Early Studies
- Sofosbuvir/Ledipasvir Coformulation Shows Good Early Response With or Without Ribavirin
- EASL 2013: Triple Therapy for Hepatitis C Is Effective after Liver Transplantation but Comes with Side Effects
- Direct-acting Antivirals Could Dramatically Reduce Hepatitis C Transmission among IDUs
- EASL 2013: Vaniprevir Boosts Interferon/Ribavirin Response Rate for Prior Non-Responders with Cirrhosis
Web Design and Development by